Loading [Contrib]/a11y/accessibility-menu.js
prnano
  • Menu
  • Articles
    • Communications
    • Editorials
    • Letters to the Editor
    • Perspective, Opinion, or Discussion
    • Policies
    • Research Articles
    • Reviews
    • Technical Notes
    • All
  • For Authors
  • Editorial Board
  • About
  • Issues
  • Blog
  • The Rising Talents List
  • Journal Policies
  • search

    Sorry, something went wrong. Please try your search again.
    ×

    • Articles
    • Blog posts

RSS Feed

Enter the URL below into your favorite RSS reader.

https://precisionnanomedicine.com/feed
×
Research Articles
Vol. 1, Issue 3, 2018 September 25, 2018 EDT

Nanoparticle-Encapsulated Doxorubicin Demonstrates Superior Tumor Cell Kill in Triple Negative Breast Cancer Subtypes Intrinsically Resistant to Doxorubicin

Adam Friedman , Kenny Ye , Alicia Rodriguez-Gabin , Joshua Nosanchuk , Joel Friedman , Alan Alfieri , Mahantesh Navanti , Angelo Landriscina , Jamie Rosen , David Schairer , Joy Makdisi , Brandon Adler , Aimee Krausz , Hayley McDaid ,
  • experimental therapeutics
  • nanoparticles
  • triple-negative breast cancer
  • doxorubicin
  • drug resistance
ccby-nc-sa-4.0 • https://doi.org/10.33218/prnano1(3).181029.1
prnano
Friedman, Adam, Kenny Ye, Alicia Rodriguez-Gabin, Joshua Nosanchuk, Joel Friedman, Alan Alfieri, Mahantesh Navanti, et al. 2018. “Nanoparticle-Encapsulated Doxorubicin Demonstrates Superior Tumor Cell Kill in Triple Negative Breast Cancer Subtypes Intrinsically Resistant to Doxorubicin.” Precision Nanomedicine 1 (3): 173–82. https://doi.org/10.33218/prnano1(3).181029.1.
Save article as...▾
  • PDF
  • XML
  • Citation (BibTeX)
Powered by Scholastica, the modern academic journal management system